TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) announced it has initiated a Phase II study of NGX267, a muscarinic agonist in development for xerostomia, or dry mouth, secondary to Sjogren’s syndrome. The company is conducting a randomized, double-blind, placebo-controlled, cross-over study with a Latin square design to evaluate the safety, tolerability and efficacy of this once-a-day compound.

More: continued here

This entry was posted on Wednesday, April 2nd, 2008 at 5:04 pm and is filed under Endocrinology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.